Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 5, 2013, Pages 647-655

  Pina, J M ^a,b,f   Clotet, L ^a,b,f   Ferrer, A ^b,f   Sala, M R ^c,f   Garrido, P ^d,g   Salleras, L ^d,e,g   Dominguez A ^d,e,g  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b CNMI Division of Public Health   (Spain)

^c Generalitat of Catalonia   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f Unitat de Vigilancia Epidemiologica Valles Occidental i Valles Oriental Programa de Tuberculosi   (Spain)

^g NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIGESTIVE INTOLERANCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HYPERSENSITIVITY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEURITIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; ANTITUBERCULAR AGENTS; CONTACT TRACING; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; RETROSPECTIVE STUDIES; RIFAMPIN; SPAIN; TUBERCULOSIS;

EID: 84877876550     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1788-2     Document Type: Article

References (33)

1. World Health Organization (WHO) (2011) Global tuberculosis control. WHO report, pp 1-28
2. Dye C, Williams BG (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5:653-662
3. Rieder HL (2002) Interventions for tuberculosis control and elimination. International Union Against Tuberculosis and Lung Disease, Paris, pp 15-95, 127-147
4. Holland DP, Sanders GD, Hamilton CD, Stout JE (2009) Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 179:1055-1060
5. Esfahani K, Aspler A, Menzies D, Schwartzman K (2011) Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis 15:1340-1346
6. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC) (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54(RR-15):1-47
7. ATS/CDC Statement Committee on Latent Tuberculosis Infection (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49(RR-6):1-51
8. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952
9. Muennig P (2008) Cost-effectiveness analysis in health: a practical approach, 2nd edn. Jossey-Bass, San Francisco, pp 19-35
10. Zilberberg MD, Shorr AF (2010) Understanding cost-effectiveness. Clin Microbiol Infect 16:1707-1712
11. Agencia Española de Medicamentos (2006) Información de medicamentos autorizados en España. Ministerio de Sanidad y Consumo. In: Guia de prescrición terapéutica (GPT): Pharma, Barcelona: 309
12. Institut Català de la Salut (2008) Resolució slt/434/2008, de 12 de Febrer: Revisió de preus públics corresponents als serveis sanitaris que presta l'Institut Català de la Salut. Diari Oficial de la Generalitat de Catalunya Núm 5076-22. February 2008
13. Nomenclator del Colegio Oficial de Médicos de Barcelona (2009) Available online at: http://www.comb.cat/nomenclator. Accessed 7 Feb 2011
14. American Thoracic Society; CDC; Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR Recomm Rep 52(RR-11):1-77
15. Agencia de Calidad del Servicio Nacional de Salud, Instituto de Información Sanitaria (2009) Norma estatal de los AP GRD v23. Ministerio de Sanidad, Política Social e Igualdad: Spain. Available online at: http://www.mspsi.es/estadEstudios/estadisticas/cmbd.htm. Accessed 11 Feb 2011
16. International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 60:555-564
17. World Health Organization (WHO) (2008) Anti-tuberculosis drug resistance in the world. Report no. 4, pp 35-53
18. Vynnycky E, Fine PE (1997) The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119:183-201
19. Morán-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM (2010) Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 14:1112-1119
20. Dutt AK, Stead WW (1999) Epidemiology and host factors. In: Schlossberg D (ed) Tuberculosis and nontuberculous mycobacterial infections. W. B. Saunders, Philadelphia, pp 3-16
21. Nardel EA, Fennelly KP (2006) Tuberculosis transmission and infection control in congregate settings. In: Raviglione MC (ed) Reichman and Hershfield's tuberculosis: a comprehensive, international approach. Informa Healthcare, London, pp 793-821
22. Reichman LB, Lardizabal A, Hayden CH (2004) Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 170:832-835
23. Straus SE, Glasziou P, Richardson WS, Haynes RB (2006) Evidence-based medicine. Elsevier, Madrid, pp 115-177, 263-277
24. Pina-Gutiérrez JM, Ferrer-Traid A, Arias C, Sala-Farré MR, López-Sanmartín JL (2008) Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients. Med Clin (Barc) 130:165-171
25. Bran C, Gómez i Prat J, Caylá JA, García de Olalla P (2006) Factors associated with latent tuberculous infection in immigrants less than 35 years old. Enferm Infecc Microbiol Clin 24:322-325
26. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K (2004) Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170:445-449
27. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L et al (2006) Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166:1863-1870
28. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB (2006) Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 130:1712-1717
29. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H et al (2008) Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149:689-697
30. Ziakas PD, Mylonakis E (2009) 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 49:1883-1889
31. Hong Kong Chest Service/Tuberculosis Research Centre; Madras/British Medical Research Council (1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145:36-41
32. Argimón JM, Jiménez J (1995) Métodos de investigación aplicados a la atención primaria de salud. Mosby/Doyma Libros, Barcelona, pp 91-100
33. Comstock GW (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3:847-850